A British Pharmacological Society event
Stem cell derived therapies are complex and diverse, so it is critical that we understand the challenges faced in getting clinical trials for these therapies approved.
Across two days, we will discuss how some therapies have made progress towards clinical trials, particularly in relation to assessing safety. We will also look at areas where new technologies can fill vital gaps, such as in combination therapies with smart materials.
This meeting will be of particular interest to pharmacologists, those working in toxicology, clinicians, academics and industry. Regulators, including MHRA and FDA, will also be joining our panel discussions.
Hear from leaders in the field including Pete Coffey, Agnete Kirkeby, Martin Pera, Kevin Eggan, David Hay, Richard Adair, Sarah Waters and our key note speaker, Jane Lebkowski.
For further details and to register please visit the event webpage
Continuing Professional Development (CPD)
This event is approved by the Royal Society of Biology for purposes of CPD
and may be counted as 42 CPD credits